Literature DB >> 9804782

The intracellular localization of deoxycytidine kinase.

P Hatzis1, A S Al-Madhoon, M Jüllig, T G Petrakis, S Eriksson, I Talianidis.   

Abstract

Deoxycytidine kinase (dCK) catalyzes the rate-limiting step of the deoxynucleoside salvage pathway in mammalian cells and plays a key role in the activation of several pharmacologically important nucleoside analogs. Using a highly specific polyclonal antibody raised against a C-terminal peptide of the human dCK, we analyzed its subcellular localization by Western blots of biochemically fractionated nuclear and cytoplasmic fractions as well as by in situ immunochemistry. Native dCK was found to be located mainly in the cytoplasm in several cell types, and the enzyme was more concentrated in the perinuclear and cellular membrane area. In contrast, when dCK was overexpressed in the cells, it was mainly located in the nucleus. The results demonstrate that native dCK is a cytoplasmic enzyme. However, it has the ability to enter the nucleus under certain conditions, suggesting the existence of a cytoplasmic retention mechanism that may have an important function in the regulation of the deoxynucleoside salvage pathway.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9804782     DOI: 10.1074/jbc.273.46.30239

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.

Authors:  Valeria Sebastiani; Francesca Ricci; Belen Rubio-Viqueira; Belen Rubio-Viquiera; Piotr Kulesza; Charles J Yeo; Manuel Hidalgo; Alison Klein; Daniel Laheru; Christine A Iacobuzio-Donahue
Journal:  Clin Cancer Res       Date:  2006-04-15       Impact factor: 12.531

2.  Protein inhibitor of activated STAT1 interacts with and up-regulates activities of the pro-proliferative transcription factor Krüppel-like factor 5.

Authors:  James X Du; C Chris Yun; Agnieszka Bialkowska; Vincent W Yang
Journal:  J Biol Chem       Date:  2006-12-18       Impact factor: 5.157

3.  Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach.

Authors:  James J Farrell; Jennifer Moughan; Jonathan L Wong; William F Regine; Paul Schaefer; Al B Benson; John S Macdonald; Xiyong Liu; Yun Yen; Raymond Lai; Zhong Zheng; Gerold Bepler; Chandan Guha; Hany Elsaleh
Journal:  Pancreas       Date:  2016-11       Impact factor: 3.327

4.  Zidovudine induces downregulation of mitochondrial deoxynucleoside kinases: implications for mitochondrial toxicity of antiviral nucleoside analogs.

Authors:  Ren Sun; Staffan Eriksson; Liya Wang
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

5.  dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.

Authors:  Florencia McAllister; Danielle M Pineda; Masaya Jimbo; Shruti Lal; Richard A Burkhart; Jennifer Moughan; Kathryn A Winter; Kotb Abdelmohsen; Myriam Gorospe; Ana de Jesus Acosta; Rachana H Lankapalli; Jordan M Winter; Charles J Yeo; Agnieska K Witkiewicz; Christine A Iacobuzio-Donahue; Daniel Laheru; Jonathan R Brody
Journal:  Cancer Biol Ther       Date:  2014-03-11       Impact factor: 4.742

6.  Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours.

Authors:  I Hubeek; G J Peters; A J F Broekhuizen; I Talianidis; J Sigmond; B E S Gibson; U Creutzig; G Giaccone; G J L Kaspers
Journal:  J Clin Pathol       Date:  2005-07       Impact factor: 3.411

7.  A few amino acid substitutions can convert deoxyribonucleoside kinase specificity from pyrimidines to purines.

Authors:  Wolfgang Knecht; Michael P B Sandrini; Kenth Johansson; Hans Eklund; Birgitte Munch-Petersen; Jure Piskur
Journal:  EMBO J       Date:  2002-04-02       Impact factor: 11.598

8.  Mimicking phosphorylation of Ser-74 on human deoxycytidine kinase selectively increases catalytic activity for dC and dC analogues.

Authors:  Theresa McSorley; Stephan Ort; Saugata Hazra; Arnon Lavie; Manfred Konrad
Journal:  FEBS Lett       Date:  2008-02-05       Impact factor: 4.124

9.  Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines.

Authors:  A M Bergman; H M Pinedo; I Talianidis; G Veerman; W J P Loves; C L van der Wilt; G J Peters
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

10.  Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.

Authors:  Stacy S Shord; Shitalben R Patel
Journal:  J Exp Clin Cancer Res       Date:  2009-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.